منابع مشابه
The rationale for thrombolytic therapy.
Substantial progress has been made toward understanding the pathophysiological processes that lead to acute myocardial infarction. Research has shown that the mechanism of infarction is the rupture of an atherosclerotic plaque with a subsequent thrombogenic response from exposed subendothelial tissue, leading to additional or complete obstruction of the vessel. Myocardial cell death then procee...
متن کاملRationale for a nanomedicine approach to thrombolytic therapy.
Stroke is the third-leading cause of death and most common etiology for long-term adult disability. Of the approximate 700 000 individuals experiencing new or recurrent stroke annually, less than 5% of these individuals receive thrombolytic therapy.1–3 Intravenous recombinant tissue plasminogen activator (rt-PA) is an approved pharmacological treatment for acute ischemic stroke, but the window ...
متن کاملThrombolytic therapy for stroke
Stroke is a common condition affecting approximately 110,000 people every year in England alone. It is the third leading cause of death and the single largest cause of adult physical disability [1]. A third of individuals who have a stroke are left with a long-term disability that may include weakness, sensory impairment and loss of cognitive and communication skills, depending on the regions o...
متن کاملThrombolytic therapy.
Thrombolytic therapy, which involves the administration of agents designed to increase fibrinolytic capacity, has been utilized in respiratory medicine for more than 50 years. A variety of agents have been used to effect thrombolysis, including urokinase plasminogen activator (uPA) and streptokinase. Tissue plasminogen activator (tPA) has also been used to effect thrombolysis. Both uPA and tPA ...
متن کاملThrombolytic Therapy.
The purpose of this communication is to review briefly the agents available at the present time for use in thrombolytic therapy and to indicate why we believe that at the present time streptokinase is the only suitable agent for extended clinical trial. An account will then be given of the use of streptokinase administered by local perfusion in the treatment of peripheral arterial occlusion and...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Heart Journal
سال: 1996
ISSN: 0195-668X,1522-9645
DOI: 10.1093/eurheartj/17.suppl_e.2